Celerion, Inc.
Tempe, Arizona, 85283, United States
Location status: Recruiting
NCT Number: NCT07177066
The purposes of this Phase 1 study of EDG-15400 are to:
1. Learn about the safety of EDG-15400 after single and multiple doses in healthy adults 2. Learn about how EDG-15400 is tolerated after single and multiples doses in healthy adults 3. Evaluate the amount of EDG-15400 in the blood and urine after single and multiple doses in healthy adults 4. Evaluate the effect of a meal on the amount of EDG-15400 that is in the blood in healthy adults 5. Evaluate whether the amount of EDG-15400 in the blood is similar for the suspension and tablet forms of EDG-15400 in healthy adults
Participants will receive a single or multiple doses of EDG-15400 or a placebo by mouth.
Interested in participating?
Request Info18 year–59 year
All sexes
Interventional
Phase 1
Tempe, Arizona, 85283, United States
Location status: Recruiting
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Additional protocol defined inclusion/exclusion criteria may apply.
EDG-15400 is administered orally
Placebo is administered orally
Time frame: Up to 25 days of monitoring
To determine the safety and tolerability of EDG-15400 when administered as single and multiple ascending doses to healthy adults
Time frame: Up to 25 days
Time to maximum concentration (Tmax)
Time frame: Up to 25 days
Maximum observed concentration (Cmax)
Time frame: Up to 25 days
Area under the concentration-time curve (AUC)
Time frame: Up to 25 days
Elimination half-life (t1/2)
Time frame: Up to 25 days
Apparent volume of distribution after oral administration (V/F)
Time frame: Up to 25 days
Apparent clearance of drug after oral administration (CL/F)
Time frame: Up to 25 days
Renal clearance (CLr)
Contact information is provided by the study sponsor or research team.
Edgewise Therapeutics, Inc.
Industry
A Phase 1, Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of EDG-15400 in Healthy Adults
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07732166
Healthy Adults
Rio de Janeiro, Brazil
View Trial DetailsNCT07695168
Healthy Adults, Knee Osteoarthristis
Taipei, Taiwan
View Trial DetailsNCT05918679
Healthy Adults
Tempe, Arizona, United States
View Trial DetailsNCT07660731
Asthma, Bronchial Diseases
New Haven, Connecticut, United States
View Trial Details